Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
New Ray Medicine International Holding Ltd. ( (HK:6108) ) has issued an update.
New Ray Medicine International Holding Ltd. reported a significant revenue increase of 167.4% for the first half of 2025, reaching approximately HK$44.7 million compared to the same period in 2024. Despite the revenue growth, the company experienced a net loss increase of 82.3%, totaling approximately HK$7.5 million. The board decided against paying an interim dividend, and the company maintained a gearing ratio of zero, indicating no bank or other borrowings relative to total equity. The financial results reflect both the potential for revenue growth and the challenges in managing costs and losses, impacting stakeholders’ perspectives on the company’s financial health.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. operates in the pharmaceutical industry, focusing on the distribution and trading of pharmaceutical products. The company is incorporated in Bermuda and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 370,701
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$68.55M
For a thorough assessment of 6108 stock, go to TipRanks’ Stock Analysis page.